AbbVie (NYSE:ABBV) Updates Q2 2026 Earnings Guidance

Key Points

• Q2 guidance: AbbVie set EPS guidance of 3.740–3.780 (in line with consensus) but guided revenue of $16.7B versus the $16.8B consensus, and the stock fell about 2.2% on the update.
• Q1 beat and growth drivers: AbbVie topped Q1 estimates with $2.65 EPS and revenue up 12.4% year‑over‑year, driven by immunology drugs like Skyrizi and Rinvoq, helping push a consensus "Moderate Buy" rating and an average price target of $252.90.
• Dividend and sentiment risks: The company declared a quarterly dividend of $1.73 ($6.92 annualized, 3.3% yield) but has a high payout ratio (293%) and recent insider selling, which may weigh on near‑term investor sentiment.

AbbVie (NYSE:ABBV - Get Free Report) issued an update on its second quarter 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 3.740-3.780 for the period, compared to the consensus earnings per share estimate of 3.740. The company issued revenue guidance of $16.7 billion-$16.7 billion, compared to the consensus revenue estimate of $16.8 billion.

AbbVie Stock Down 2.2%

NYSE ABBV traded down $4.69 during trading hours on Friday, reaching $206.63. The company's stock had a trading volume of 6,339,492 shares, compared to its average volume of 7,231,846. The firm's 50-day moving average price is $214.55 and its 200-day moving average price is $221.60. AbbVie has a 1 year low of $176.57 and a 1 year high of $244.81. The company has a market capitalization of $365.36 billion, a price-to-earnings ratio of 101.79, a PEG ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to analysts' expectations of $14.72 billion. During the same period in the previous year, the firm earned $2.46 EPS. The firm's revenue was up 12.4% compared to the same quarter last year. Equities research analysts anticipate that AbbVie will post 14.13 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio is 293.22%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ABBV shares. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a report on Thursday, February 5th. Evercore decreased their price objective on AbbVie from $232.00 to $228.00 and set an "outperform" rating on the stock in a report on Wednesday, February 4th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $240.00 price objective on shares of AbbVie in a report on Thursday. Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, Canaccord Genuity Group upped their price objective on AbbVie from $262.00 to $265.00 and gave the stock a "buy" rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and an average price target of $252.90.

Insider Buying and Selling at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company's stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

Institutional Trading of AbbVie

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp grew its position in AbbVie by 1.4% in the 4th quarter. State Street Corp now owns 80,940,931 shares of the company's stock valued at $18,494,193,000 after acquiring an additional 1,119,274 shares during the last quarter. Bank of America Corp DE grew its position in AbbVie by 1.4% in the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company's stock valued at $5,900,617,000 after acquiring an additional 356,394 shares during the last quarter. Wellington Management Group LLP grew its position in AbbVie by 41.7% in the 4th quarter. Wellington Management Group LLP now owns 14,926,683 shares of the company's stock valued at $3,410,598,000 after acquiring an additional 4,389,782 shares during the last quarter. Amundi grew its position in AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock valued at $2,418,909,000 after acquiring an additional 1,414,621 shares during the last quarter. Finally, Raymond James Financial Inc. grew its position in AbbVie by 2.4% in the 3rd quarter. Raymond James Financial Inc. now owns 9,557,701 shares of the company's stock valued at $2,212,110,000 after acquiring an additional 220,221 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.